Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

    August 24, 2024
    ConferencesASCO2023
    ConferencesASCO2023
    Share This:

    Key Points

    TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations
    CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma
    CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma
    THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration
    Dr. Toni Choueiri
    Profile

    Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights

    Focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School – Dana-Farber Cancer Institute.

    Tags:

    Related Posts

    ConferencesWCLC2025ArticlesSeptember 18, 2025
    WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
    ConferencesASCO2025July 31, 2025
    Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer